Dyslipidemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Dyslipidemia – Pipeline Review, H2 2017’, provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dyslipidemia

The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects

The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dyslipidemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dyslipidemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acasti Pharma Inc

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

AstraZeneca Plc

BASF SE

BCWorld Pharm Co Ltd

Bioleaders Corp

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Cadila Pharmaceuticals Ltd

Cardax Inc

Catabasis Pharmaceuticals Inc

Celon Pharma SA

Cerenis Therapeutics Holding SA

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Connexios Life Sciences Pvt Ltd

CymaBay Therapeutics Inc

Daewon Pharm Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

Eli Lilly and Company

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

HanAll Biopharma Co Ltd

Handok Inc

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Hyundai Pharmaceutical Co Ltd

Innovent Biologics Inc

InStar Technologies AS

Jeil Pharmaceutical Co Ltd

JW Pharmaceutical Corp

Kotobuki Pharmaceutical Co Ltd

Kowa Company Ltd

Kuhnil Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipicard Technologies Ltd

Lipigon Pharmaceuticals AB

LipimetiX Development Inc

Lotus Pharmaceutical Co Ltd

Nippon Chemiphar Co Ltd

Omeros Corp

Pfizer Inc

Pharmena SA

Protalix BioTherapeutics Inc

Regeneron Pharmaceuticals Inc

Samjin Pharm Co Ltd

Sancilio & Company Inc

Takeda Pharmaceutical Company Ltd

Tasly Pharmaceutical Group Co Ltd

Torrent Pharmaceuticals Ltd

Viking Therapeutics Inc

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Dyslipidemia - Overview 7

Dyslipidemia - Therapeutics Development 8

Dyslipidemia - Therapeutics Assessment 23

Dyslipidemia - Companies Involved in Therapeutics Development 35

Dyslipidemia - Drug Profiles 65

Dyslipidemia - Dormant Projects 252

Dyslipidemia - Discontinued Products 261

Dyslipidemia - Product Development Milestones 265

Appendix 277

List of Tables

List of Tables

Number of Products under Development for Dyslipidemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dyslipidemia – Pipeline by Acasti Pharma Inc, H2 2017

Dyslipidemia – Pipeline by Akcea Therapeutics Inc, H2 2017

Dyslipidemia – Pipeline by Alnylam Pharmaceuticals Inc, H2 2017

Dyslipidemia – Pipeline by Amgen Inc, H2 2017

Dyslipidemia – Pipeline by AstraZeneca Plc, H2 2017

Dyslipidemia – Pipeline by BASF SE, H2 2017

Dyslipidemia – Pipeline by BCWorld Pharm Co Ltd, H2 2017

Dyslipidemia – Pipeline by Bioleaders Corp, H2 2017

Dyslipidemia – Pipeline by BioRestorative Therapies Inc, H2 2017

Dyslipidemia – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Cadila Healthcare Ltd, H2 2017

Dyslipidemia – Pipeline by Cadila Pharmaceuticals Ltd, H2 2017

Dyslipidemia – Pipeline by Cardax Inc, H2 2017

Dyslipidemia – Pipeline by Catabasis Pharmaceuticals Inc, H2 2017

Dyslipidemia – Pipeline by Celon Pharma SA, H2 2017

Dyslipidemia – Pipeline by Cerenis Therapeutics Holding SA, H2 2017

Dyslipidemia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Dyslipidemia – Pipeline by CJ HealthCare Corp, H2 2017

Dyslipidemia – Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017

Dyslipidemia – Pipeline by CymaBay Therapeutics Inc, H2 2017

Dyslipidemia – Pipeline by Daewon Pharm Co Ltd, H2 2017

Dyslipidemia – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Dyslipidemia – Pipeline by Eli Lilly and Company, H2 2017

Dyslipidemia – Pipeline by Esperion Therapeutics Inc, H2 2017

Dyslipidemia – Pipeline by Gemphire Therapeutics Inc, H2 2017

Dyslipidemia – Pipeline by Gilead Sciences Inc, H2 2017

Dyslipidemia – Pipeline by GlaxoSmithKline Plc, H2 2017

Dyslipidemia – Pipeline by Golden Biotechnology Corp, H2 2017

Dyslipidemia – Pipeline by HanAll Biopharma Co Ltd, H2 2017

Dyslipidemia – Pipeline by Handok Inc, H2 2017

Dyslipidemia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Dyslipidemia – Pipeline by Huons Global Co Ltd, H2 2017

Dyslipidemia – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Innovent Biologics Inc, H2 2017

Dyslipidemia – Pipeline by InStar Technologies AS, H2 2017

Dyslipidemia – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by JW Pharmaceutical Corp, H2 2017

Dyslipidemia – Pipeline by Kotobuki Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Kowa Company Ltd, H2 2017

Dyslipidemia – Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Lipicard Technologies Ltd, H2 2017

Dyslipidemia – Pipeline by Lipigon Pharmaceuticals AB, H2 2017

Dyslipidemia – Pipeline by LipimetiX Development Inc, H2 2017

Dyslipidemia – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017

Dyslipidemia – Pipeline by Nippon Chemiphar Co Ltd, H2 2017

Dyslipidemia – Pipeline by Omeros Corp, H2 2017

Dyslipidemia – Pipeline by Pfizer Inc, H2 2017

Dyslipidemia – Pipeline by Pharmena SA, H2 2017

Dyslipidemia – Pipeline by Protalix BioTherapeutics Inc, H2 2017

Dyslipidemia – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Dyslipidemia – Pipeline by Samjin Pharm Co Ltd, H2 2017

Dyslipidemia – Pipeline by Sancilio & Company Inc, H2 2017

Dyslipidemia – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Dyslipidemia – Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017

Dyslipidemia – Pipeline by Torrent Pharmaceuticals Ltd, H2 2017

Dyslipidemia – Pipeline by Viking Therapeutics Inc, H2 2017

Dyslipidemia – Pipeline by Yuhan Corp, H2 2017

Dyslipidemia – Dormant Projects, H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..2), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..3), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..4), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..5), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..6), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..7), H2 2017

Dyslipidemia – Dormant Projects, H2 2017 (Contd..8), H2 2017

Dyslipidemia – Discontinued Products, H2 2017

Dyslipidemia – Discontinued Products, H2 2017 (Contd..1), H2 2017

Dyslipidemia – Discontinued Products, H2 2017 (Contd..2), H2 2017

Dyslipidemia – Discontinued Products, H2 2017 (Contd..3), H2 2017

List of Figures

List of Figures

Number of Products under Development for Dyslipidemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports